Hepatic lipid metabolism pathway

Hepatic lipid metabolism pathways refer collectively to the complex network of biochemical processes in the liver governing the uptake, synthesis (*de novo* lipogenesis), oxidation (β-oxidation), and export of fatty acids and other lipids[1][4][5]. These interconnected processes maintain systemic energy balance and lipid homeostasis and are regulated by key enzymes (e.g., acetyl-CoA carboxylase, fatty acid synthase), transcription factors (e.g., SREBP1c, ChREBP), and hormones (e.g., insulin, thyroid hormone)[1][4]. Dysregulation of hepatic lipid metabolic pathways is central to the development of fatty liver diseases (including MAFLD/NAFLD), dyslipidemias, and atherosclerosis. While the molecular machinery within these pathways (such as specific enzymes or receptors) can be therapeutic targets, the term "hepatic lipid metabolism pathways" describes a biological process, not a single molecular entity, and is thus not a canonical drug target[4][5].\n\n**Note:** "Hepatic lipid metabolism pathways" refers to a process, not a discrete molecular target. The entry is best categorized as not a canonical therapeutic target (is_target: false), and is_incorrect: true for structured drug target databases. For specific drug development, the focus would shift to individual enzymes, transporters, or receptors within these pathways.

Other names

hepatic fat metabolism pathwayhepatic fatty acid metabolismliver lipid metabolic pathways

Modulation of lipid synthesis (inhibition of HMG-CoA reductase by statins)\nActivation of peroxisome proliferator-activated receptors (PPARα by fibrates)\nInhibition of de novo lipogenesis (various experimental compounds)\nEnhancement of fatty acid oxidation\nReduced VLDL secretion